The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity
Open accessPublished version of a preprint
Abstract
Abstract Mutations in tumor suppressor p53 remain a vital mechanism of tumor escape from apoptosis and senescence. Emerging evidence suggests that p53 dysfunction also fuels inflammation and supports tumor immune evasion, thereby serving as an immunological driver of tumorigenesis. Therefore, targeting p53 in the tumor microenvironment (TME) also represents an immunologically desirable strategy for reversing immunosuppression and enhancing antitumor immunity. Using a pharmacological p53 activator nutlin-3a, we show that local p53 activation in TME comprising overt tumor-infiltrating leukocytes (TILeus) induces systemic antitumor immunity and tumor regression, but not in TME with scarce TILeus, such as B16 melanoma. Maneuvers that recruit leukocytes to TME, such as TLR3 ligand in B16 tumors, greatly enhanced nutlin-induced antitumor immunity and tumor control. Mechanistically, nutlin-3a–induced antitumor immunity was contingent on two nonredundant but immunologically synergistic p53-dependent processes: reversal of immunosuppression in the TME and induction of tumor immunogenic cell death, leading to activation and expansion of polyfunctional CD8 CTLs and tumor regression. Our study demonstrates that unlike conventional tumoricidal therapies, which rely on effective p53 targeting in each tumor cell and often associate with systemic toxicity, this immune-based strategy requires only limited local p53 activation to alter the immune landscape of TME and subsequently amplify immune response to systemic antitumor immunity. Hence, targeting the p53 pathway in TME can be exploited to reverse immunosuppression and augment therapeutic benefits beyond tumoricidal effects to harness tumor-specific, durable, and systemic antitumor immunity with minimal toxicity. Cancer Res; 77(9); 2292–305. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, p53 reactivation by nutlin 3a, a pharmacological inhibitor of the p53-degrading enzyme MDM2 proto-oncogene (MDM2), elicits ICD in B16 melanomas, correlating with DC activation, expansion of tumor-infiltrating CD8 + CTLs, and depletion of immunosuppressive MDSCs (Guo et al., 2017).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Guo et al., 2017
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · cited 1×
“Experimentally and clinically, MDSCs are one of the crucial populations in enforcing immunosuppression in the TME (30,41-43).”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · cited 2×
“Nature reviews Drug discovery 2008;7(12):979-87.”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 2×
“Experimentally and clinically, MDSCs are one of the crucial populations in enforcing immunosuppression in the TME (30,41-43).”
BackgroundImmunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303 · cited 18×
“ICD is usually characterized by three hallmarks: cell surface exposure of an endoplasmic reticulum protein calreticulin (CALR), release of nuclear protein high mobility group box 1 (HMGB1), and cellular ATP to extracellular on March 10, 2017.”
BackgroundInfluentialSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent studies showed that targeted p53 activation/restoration via genetic approach activates NK cells and macrophages (15,16).”
BackgroundT cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473 · cited 1×
“Because immune cell access to tumors is essential for effective tumor control (35-37), we examined leukocyte infiltration in the B16 TME.”
BackgroundTP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 3×
“Hence, targeting the p53 pathway represents a favorable immunological strategy besides its current application as a tumoricidal regimen (2,3,10,11).”
BackgroundMyeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736 · cited 1×
“Among CD11b cells in the TME and tumor draining lymph nodes (TDLNs), CD11bGr-1 MDSCs and activated DCs exemplify functional opposing myeloid subpopulations (28,30,31).”
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
“136 p53 activation stimulates cellular anti-tumor responses, 137,138 leading to interferon production, and there is a synergistic effect between cancer immunotherapy.”
BackgroundA single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
Huang, A. C., Orlowski, R. J., Xu, X., Mick, R., George, S. M., Yan, P. K., Manne, S., Kraya, A. A., Wubbenhorst, B., Dorfman, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0357-y · Cited by 686
Targeting p53 for the treatment of cancer
Duffy, M. J., Synnott, N. C., O’Grady, S., & Crown, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.005 · Cited by 349
p53, cancer and the immune response
Blagih, J., Buck, M. D., & Vousden, K. H. (2020) · Journal of Cell Science · doi:10.1242/jcs.237453 · Cited by 333
“In line with this, local stabilization of p53 reprograms suppressive myeloid populations towards effective APCs and induces tumour regression in some, but not all, subcutaneous cancer models (Guo et al., 2017) (Fig.”
BackgroundThe p53 network: cellular and systemic DNA damage responses in cancer and aging
Vaddavalli, P. L., & Schumacher, B. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.02.010 · Cited by 279
Metadata
- Authors
- Guo, G., Yu, M., Xiao, W., Celis, E., & Cui, Y.
- Affiliations
- Augusta University (US)
- Corresponding author
- Cui, Yan
- Venue
- Cancer Research
- Published
- 2017-04-30
- Volume
- 77
- Issue
- 9
- Pages
- 2292-2305
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC5465961
- OpenAlex
- W2593361213
- Cited by
- 168
- References
- 48
- Citations by year
- 2026: 4 · 2025: 16 · 2024: 32 · 2023: 21 · 2022: 24 · 2021: 28 · 2020: 20 · 2019: 13 · 2018: 9 · 2017: 1
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NCI NIH (01CA169133, R01CA157303)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- p53 activation, tumor microenvironment, Nutlin-3a, immunosuppression reversal, antitumor immunity, tumor-infiltrating leukocytes, CD8+ T cells, TLR3 ligand, B16 melanoma
- MeSH terms
- Animals, Humans, Imidazoles, Immunity, Innate, Immunosuppression Therapy, Melanoma, Experimental, Mutation, Piperazines, T-Lymphocytes, Cytotoxic, Tumor Suppressor Protein p53, Lymphocytes, Tumor-Infiltrating, Apoptosis, Mice, Tumor Microenvironment, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-2832
- The paper
- Guo, G., Yu, M., Xiao, W., Celis, E., & Cui, Y. (2017). Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-2832
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.